Krystal Biotech, Inc. Available-for-sale Securities, Gross Unrealized Gain
Krystal Biotech, Inc. (KRYS) reported Available-for-sale Securities, Gross Unrealized Gain of $14.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-07.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains · last filed 2019-05-07
- Krystal Biotech, Inc. available-for-sale securities, gross unrealized gain for the quarter ending 2019-03-31 was $14.00K.
- Krystal Biotech, Inc. available-for-sale securities, gross unrealized gain for the quarter ending 2018-09-30 was $3.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Gain 3 month | Available-for-sale Securities, Gross Unrealized Gain 9 month |
|---|---|---|
| 2019-03-31 | $14.00K 10-Q · filed 2019-05-07 | |
| 2018-09-30 | $3.00K 10-Q · filed 2018-11-05 | $1.00K 10-Q · filed 2018-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |